[go: up one dir, main page]

US20140256696A1 - Steroid conjugates - Google Patents

Steroid conjugates Download PDF

Info

Publication number
US20140256696A1
US20140256696A1 US14/199,514 US201414199514A US2014256696A1 US 20140256696 A1 US20140256696 A1 US 20140256696A1 US 201414199514 A US201414199514 A US 201414199514A US 2014256696 A1 US2014256696 A1 US 2014256696A1
Authority
US
United States
Prior art keywords
oxo
phenanthren
cyclopenta
dihydroxy
dodecahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/199,514
Other languages
English (en)
Inventor
Santosh C. Sinha
Ken Chow
Liming Wang
Michael E. Garst
Mayssa Attar
Brandon D. Swift
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50382692&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20140256696(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Priority to US14/199,514 priority Critical patent/US20140256696A1/en
Assigned to ALLERGAN, INC. reassignment ALLERGAN, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ATTAR, MAYSSA, SWIFT, BANDON D., CHOW, KEN, GARST, MICHAEL E., SINHA, SANTOSH C., WANG, LIMING
Publication of US20140256696A1 publication Critical patent/US20140256696A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A61K47/481—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides

Definitions

  • the present invention describes steroid conjugates. These single drug entities are formed by connecting two or more steroids via a linker. Upon topical application to the eye, the conjugate hybrid would undergo enzymatic and/or hydrolytic cleavage to release the individual steroid drugs.
  • a conjugate drug also referred to as a co-drug, a pro-drug, or a hybrid drug, comprises two or more different or same drugs within one single chemical entity wherein each drug contains an appropriate chemical functionality to enable them to be connected together, either directly or by means of a covalent linker, which is cleavable, biologically labile.
  • Hybrid structures can incorporate two drugs joined together by a linker moiety such as an ester, a carboxylate, a carbonyl, a carbonate, an amido, a carbamate, a ketone, an amino, an oxo, an ethylene glycol, a polyethylene glycol, which is cleaved enzymatically or hydrolytically in vivo to release the active drugs.
  • a linker moiety such as an ester, a carboxylate, a carbonyl, a carbonate, an amido, a carbamate, a ketone, an amino, an oxo, an ethylene glycol, a polyethylene glycol, which is cleaved enzymatically or hydrolytically in vivo to release the active drugs.
  • each bond has a chemical functionality such as an ester, a carbonate, an amide, a carbamate, an ether, an oxo, a ketone, an amine.
  • the single drug entity can have one ether bond connecting to one steroid and one ester bond connecting to the other steroid or one ester bond connecting to each steroid or one ether bond connecting each steroid.
  • Degradation of these covalent bonds generally, yields the corresponding acid, or alcohol by hydrolysis or a by related reaction.
  • a compound which degrades in vivo to yield the individual steroids produces the active steroid drugs at some point in the metabolic process of the claimed compound. In many cases, cleavage of the first ester bond will release one active, and cleavage of the second ester bond will release the second active.
  • the hybrid drugs of the invention provide a unique delivery of two steroids for the treatment of ophthalmic bacterial infections and for the prevention of inflammation and infection.
  • a single drug entity is advantageous to individual dosing of each drug because of the ability for simultaneous dosing and elimination of washout concerns when applying each drug separately.
  • the use of an anti-inflammatory hybrid drug is indicated where the risk of infection is high.
  • the anti-inflammatory component of the composition is useful in treating inflammation associated with physical trauma to ophthalmic tissues, inflammation associated with bacterial infections and inflammation resulting from surgical procedures.
  • the composition of the invention may also be used prophylactically in connection with various ophthalmic surgical procedures that create a risk of bacterial infection.
  • Other examples of ophthalmic conditions which may be treated with the compositions of the present invention include infective conditions associated with inflammation and where the use of anti-inflammatory is acceptable.
  • Such conditions may include, but are not limited to conjunctivitis, keratitis, blepharitis, endophthalmitis, dacyrocystitis, hordeolum, corneal ulcers, anterior blepharitis, red eye, hyperemia, posterior blepharitis, meibomian gland dysfunction, dry eye disease (keratocojunctivitis sicca) ocular pain, red eye, hyperemia, ocular pain and inflammation post-ocular surgery, bacterial conjunctivitis, anterior uveitis, post-surgical inflammation, inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, such as allergic conjunctivitis, ocular rosacea, dry eye, blepharitis, meibomian gland dysfunction, superficial punctate keratitis, herpes zoster keratitis, ulceris, cyclitis, selected infective conjunctivitis, corneal injury from chemical radiation,
  • the compounds disclosed herein comprise at least one steroidal drug selected from, but not limited to: dexmethasone, betamethasone, triamcinolone acetonide, prednisolone and hydrocortisone.
  • the invention provides the compounds represented by a hybrid drug as described below.
  • the invention provides compounds which may comprise a linker moiety selected from, but not limited to, an ester, a carboxylate, a carbonyl, a carbonate, an amido, a carbamate, a ketone, an amino, an oxo, an ethylene glycol, a polyethylene glycol, an ethylene.
  • a linker moiety selected from, but not limited to, an ester, a carboxylate, a carbonyl, a carbonate, an amido, a carbamate, a ketone, an amino, an oxo, an ethylene glycol, a polyethylene glycol, an ethylene.
  • the invention provides compounds which may comprise a linker moiety comprising any combination of an ester, a carboxylate, a carbonyl, a carbonate, an amido, a carbamate, a ketone, an ethylene, an amino, an oxo, an ethylene glycol and/or a polyethylene glycol.
  • linkers moieties and linker structures are exemplified in Table 1.
  • ester moieties comprised in the linkers are:
  • Examples of carboxylate moieties comprised in the linkers are:
  • Example of a carbonate moiety comprised in the linkers is:
  • amido moieties comprised in the linkers are:
  • Example of carbamate moiety comprised in the linkers is:
  • Example of a ketone moiety comprised in the linkers is:
  • amino moieties comprised in the linkers are:
  • Example of an oxo moiety comprised in the linker is:
  • Example of ethylene glycol moieties comprised in the linkers are:
  • Example of polyethylene glycol moiety comprised in the linkers is:
  • the invention provides compounds which may comprise a linker moiety or a linker structure selected from Table 1:
  • Preferred linkers of the invention have a carbonyl functional group at each end, in order to form a carboxylate group with the oxygen atom of the steroid.
  • Preferred linkers are: L41, L42, L44, L52, L53, L54, L55, L58, L56, L57, L60, L61, L62, L63, L64, L65, L66, L67, L68, L69, L70, L71, L76, L78, L79, L80, L81, L82, L83, L84, L90, L92, L93, L94, L95, L96, L97, L98, L99, L103, L104.
  • the compounds of the invention comprise two of prednisolone moiety such as the compounds below:
  • the compounds of the invention comprise a prednisolone moiety and a betamethasone moiety as shown below:
  • the compounds of the invention comprise a prednisolone moiety and a dexamethasone moiety as shown below:
  • the compounds of the invention comprise a prednisolone moiety and a hydrocortisone moiety as shown below:
  • the compounds of the invention comprise two hydrocortisone moieties as shown below:
  • the compounds of the invention comprise a betamethasone moiety and a dexamethasone moiety as shown below:
  • the invention provides a hybrid compound comprising two steroid moieties, or a pharmaceutical salt thereof, which are separately connected via a covalent bond to a linker such that said compound degrades in vivo to yield the two steroids, wherein each bond is an ester bond.
  • the invention provides a hybrid compound wherein at least one steroid is selected from the group consisting of dexmethasone, betamethasone, triamcinolone acetonide, prednisolone and hydrocortisone.
  • the invention provides a hybrid compound, comprising two prednisolone moieties.
  • the invention provides a hybrid compound, comprising one prednisolone moiety and one betamethasone moiety.
  • the invention provides a hybrid compound, comprising one prednisolone moiety and one dexamethasone moiety.
  • the invention provides a hybrid compound, comprising one prednisolone moiety and one hydrocortisone moiety.
  • the invention provides a hybrid compound, comprising one betamethasone moiety and one dexamethasone moiety.
  • the invention provides a hybrid compound, comprising two hydrocortisone moieties.
  • the invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a hybrid compound comprising two steroid moieties, which are separately connected via a covalent bond to a linker, such that said hybrid compound degrades in vivo to yield the two steroids, wherein each bond is an ester bond, wherein said pharmaceutical composition is formulated for topical ophthalmic administration.
  • the invention provides a method comprising administration to an eye of a mammal a hybrid compound comprising two steroid moieties, which are separately connected via a covalent bond to a linker such that said hybrid compound degrades in vivo to yield the two steroids, wherein each bond is an ester bond, wherein said method is effective in the treatment of an inflammation condition affecting said eye.
  • the invention provides a method wherein said hybrid compound has topical steroid activity upon a surface of an eye, and wherein the hybrid compound degrades on said surface into one or more of said smaller active steroids which are capable of penetrating beyond tissue of said surface.
  • the invention provides a hybrid compound comprising a linker having two bonds, wherein said bonds are asymmetrically degraded in vivo to release the two steroid moieties.
  • stereogenic center may be present in an R or S configuration, said R and S notation is used in correspondence with the rules described in Pure Appli. Chem. (1976), 45, 11-13.
  • pharmaceutically acceptable salts refers to salts or complexes that retain the desired biological activity of the above identified compounds and exhibit minimal or no undesired toxicological effects.
  • pharmaceutically acceptable salts according to the invention include therapeutically active, non-toxic base or acid salt forms, which the compounds of the invention are able to form.
  • the acid addition salt form of a compound of the invention that occurs in its free form as a base can be obtained by treating the free base with an appropriate acid such as an inorganic acid, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; or an organic acid such as for example, acetic, hydroxyacetic, propanoic, lactic, pyruvic, malonic, fumaric acid, maleic acid, oxalic acid, tartaric acid, succinic acid, malic acid, ascorbic acid, benzoic acid, tannic acid, pamoic acid, citric, methylsulfonic, ethanesulfonic, benzenesulfonic, formic acid and the like (Handbook of Pharmaceutical Salts, P. Heinrich Stahl & Camille G. Wermuth (Eds), Verlag Helvetica Chimica Acta-Zürich, 2002, 329-345).
  • an appropriate acid such as an inorganic
  • the base addition salt form of a compound of the invention that occurs in its acid form can be obtained by treating the acid with an appropriate base such as an inorganic base, for example, sodium hydroxide, magnesium hydroxide, potassium hydroxide, calcium hydroxide, ammonia and the like; or an organic base such as for example, L-Arginine, ethanolamine, betaine, benzathine, morpholine and the like.
  • an appropriate base such as an inorganic base, for example, sodium hydroxide, magnesium hydroxide, potassium hydroxide, calcium hydroxide, ammonia and the like
  • an organic base such as for example, L-Arginine, ethanolamine, betaine, benzathine, morpholine and the like.
  • solvates include for example hydrates, alcoholates and the like.
  • the present invention concerns the use of a compound of the invention or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of conjunctivitis, keratitis, blepharitis, dacyrocystitis, hordeolum, corneal ulcers, anterior blepharitis, posterior blepharitis, meibomian gland dysfunction, dry eye disease (keratocojunctivitis sicca) ocular pain, ocular pain and inflammation post-ocular surgery, bacterial conjunctivitis, anterior uveitis.
  • the actual amount of the compound to be administered in any given case will be determined by a physician taking into account the relevant circumstances, such as the severity of the condition, the age and weight of the patient, the patient's general physical condition, the cause of the condition, and the route of administration.
  • the compounds of the invention may also be administered as pharmaceutical compositions in a form suitable for topical use, for example, as oily suspensions, as solutions or suspensions in aqueous liquids or nonaqueous liquids, or as oil-in-water or water-in-oil liquid emulsions.
  • compositions may be prepared by combining a therapeutically effective amount of at least one compound according to the present invention, or a pharmaceutically acceptable salt thereof, as an active ingredient with conventional ophthalmically acceptable pharmaceutical excipients and by preparation of unit dosage suitable for topical ocular use.
  • the therapeutically efficient amount typically is between about 0.001 and about 5% (w/v), preferably about 0.001 to about 2.0% (w/v) in liquid formulations.
  • solutions are prepared using a physiological saline solution as a major vehicle.
  • the pH of such ophthalmic solutions should preferably be maintained between 4.5 and 8.0 with an appropriate buffer system, a neutral pH being preferred but not essential.
  • the formulations may also contain conventional pharmaceutically acceptable preservatives, stabilizers and surfactants.
  • Preferred preservatives that may be used in the pharmaceutical compositions of the present invention include, but are not limited to, benzalkonium chloride, chlorobutanol, thimerosal, phenylmercuric acetate and phenylmercuric nitrate.
  • a preferred surfactant is, for example, Tween 80.
  • various preferred vehicles may be used in the ophthalmic preparations of the present invention. These vehicles include, but are not limited to, polyvinyl alcohol, povidone, hydroxypropyl methyl cellulose, poloxamers, carboxymethyl cellulose, hydroxyethyl cellulose cyclodextrin and purified water.
  • Tonicity adjustors may be added as needed or convenient. They include, but are not limited to, salts, particularly sodium chloride, potassium chloride, mannitol and glycerin, or any other suitable ophthalmically acceptable tonicity adjustor.
  • buffers include acetate buffers, citrate buffers, phosphate buffers and borate buffers. Acids or bases may be used to adjust the pH of these formulations as needed.
  • an ophthalmically acceptable antioxidant for use in the present invention includes, but is not limited to, sodium metabisulfite, sodium thiosulfate, acetylcysteine, butylated hydroxyanisole and butylated hydroxytoluene.
  • excipient components which may be included in the ophthalmic preparations are chelating agents.
  • the preferred chelating agent is edentate disodium, although other chelating agents may also be used in place of or in conjunction with it.
  • the ingredients are usually used in the following amounts:
  • Ingredient Amount (% w/v) active ingredient about 0.001-5 preservative 0-0.10 vehicle 0-40 tonicity adjustor 0-10 buffer 0.01-10 pH adjustor q.s. pH 4.5-7.8 antioxidant as needed surfactant as needed purified water to make 100%
  • the actual dose of the active compounds of the present invention depends on the specific compound, and on the condition to be treated; the selection of the appropriate dose is well within the knowledge of the skilled artisan.
  • the ophthalmic formulations of the present invention are conveniently packaged in forms suitable for metered application, such as in containers equipped with a dropper, to facilitate application to the eye.
  • Containers suitable for dropwise application are usually made of suitable inert, non-toxic plastic material, and generally contain between about 0.5 and about 15 ml solution.
  • One package may contain one or more unit doses.
  • Especially preservative-free solutions are often formulated in non-resealable containers containing up to about ten, preferably up to about five units doses, where a typical unit dose is from one to about 8 drops, preferably one to about 3 drops.
  • the volume of one drop usually is about 20-35 ⁇ l.
  • the patient may be administered the compound orally in any acceptable form, such as a tablet, liquid, capsule, powder and the like, or other routes may be desirable or necessary, particularly if the patient suffers from nausea.
  • routes may include, without exception, transdermal, parenteral, subcutaneous, intranasal, via an implant stent, intrathecal, intravitreal, topical to the eye, back to the eye, intramuscular, intravenous, and intrarectal modes of delivery.
  • the formulations may be designed to delay release of the active compound over a given period of time, or to carefully control the amount of drug released at a given time during the course of therapy.
  • compositions including at least one compound of the invention in a pharmaceutically acceptable carrier thereof.
  • pharmaceutically acceptable means the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • compositions of the present invention can be used in the form of a solid, a solution, an emulsion, a dispersion, a patch, a micelle, a liposome, and the like, wherein the resulting composition contains one or more compounds of the present invention, as an active ingredient, in admixture with an organic or inorganic carrier or excipient suitable for enteral or parenteral applications.
  • Invention compounds may be combined, for example, with the usual non-toxic, pharmaceutically acceptable carriers for tablets, pellets, capsules, suppositories, solutions, emulsions, suspensions, and any other form suitable for use.
  • the carriers which can be used include glucose, lactose, gum acacia, gelatin, mannitol, starch paste, magnesium trisilicate, talc, corn starch, keratin, colloidal silica, potato starch, urea, medium chain length triglycerides, dextrans, and other carriers suitable for use in manufacturing preparations, in solid, semisolid, or liquid form.
  • Invention compounds are included in the pharmaceutical composition in an amount sufficient to produce the desired effect upon the process or disease condition.
  • compositions containing invention compounds may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs.
  • Compositions intended for oral use may be prepared according to any method known in the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of a sweetening agent such as sucrose, lactose, or saccharin, flavoring agents such as peppermint, oil of wintergreen or cherry, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations.
  • Tablets containing invention compounds in admixture with non-toxic pharmaceutically acceptable excipients may also be manufactured by known methods.
  • the excipients used may be, for example, (1) inert diluents such as calcium carbonate, lactose, calcium phosphate or sodium phosphate; (2) granulating and disintegrating agents such as corn starch, potato starch or alginic acid; (3) binding agents such as gum tragacanth, corn starch, gelatin or acacia, and (4) lubricating agents such as magnesium stearate, stearic acid or talc.
  • the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
  • a time delay material such as glyceryl monostearate or glyceryl distearate may be employed.
  • formulations for oral use may be in the form of hard gelatin capsules wherein the invention compounds are mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin. They may also be in the form of soft gelatin capsules wherein the invention compounds are mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil.
  • an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin.
  • water or an oil medium for example, peanut oil, liquid paraffin or olive oil.
  • the compounds and pharmaceutical compositions described herein are useful as medicaments in mammals, including humans, for treatment of diseases and/or alleviations of conditions such as conjunctivitis, keratitis, blepharitis, dacyrocystitis, hordeolum, corneal ulcers, anterior blepharitis, posterior blepharitis, meibomian gland dysfunction, dry eye disease (keratocojunctivitis sicca) ocular pain, ocular pain and inflammation post-ocular surgery, bacterial conjunctivitis, anterior uveitis, post-surgical inflammation, inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, such as allergic conjunctivitis, ocular rosacea, dry eye, blepharitis, meibomian gland dysfunction, superficial punctate keratitis, herpes zoster keratitis, ulceris, cyclitis, selected infective conjunctivitis, corneal
  • atocojunctivitis sicca dry eye disease (keratocojunctivitis sicca) ocular pain, ocular pain and inflammation post-ocular surgery, bacterial conjunctivitis, anterior uveitis, post-surgical inflammation, inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, such as allergic conjunctivitis, ocular rosacea, dry eye, blepharitis, meibomian gland dysfunction, superficial punctate keratitis, herpes zoster keratitis, ulceris, cyclitis, selected infective conjunctivitis, corneal injury from chemical radiation, or thermal burns, penetration of foreign bodies, allergy, and
  • Such methods can be performed, for example, by administering to a subject in need thereof a pharmaceutical composition containing a therapeutically effective amount of at least one invention compound.
  • a pharmaceutical composition containing a therapeutically effective amount of at least one invention compound means the amount of the pharmaceutical composition that will elicit the biological or medical response of a subject in need thereof that is being sought by the researcher, veterinarian, medical doctor or other clinician.
  • the subject in need thereof is a mammal. In some embodiments, the mammal is human.
  • the present invention concerns also processes for preparing the hybrid compounds disclosed herein.
  • the hybrid compounds according to the invention can be prepared analogously to conventional methods as understood by the person skilled in the art of synthetic organic chemistry.
  • the synthetic scheme set forth below, illustrates how compounds according to the invention can be made. Those skilled in the art will be able to routinely modify and/or adapt the following scheme to synthesize any compounds of the invention.
  • the carboxylic intermediate can be coupled with a polyethylene glycol to form a corresponding alcohol, which can be coupled with another succinic anhydride molecule and then with another steroid of formula R′—CH 2 —OH to form a hybrid with a polyethylene and ketone moieties.
  • the compounds of the invention may contain one or more asymmetric centers, such that the compounds may exist in enantiomeric as well as in diastereomeric forms. Unless it is specifically noted otherwise, the scope of the present invention includes all enantiomers, diastereomers and racemic mixtures. Some of the compounds of the invention may form salts with pharmaceutically acceptable acids or bases, and such pharmaceutically acceptable salts of the compounds described herein are also within the scope of the invention.
  • the present invention includes all pharmaceutically acceptable isotopically enriched compounds.
  • Any compound of the invention may contain one or more isotopic atoms enriched or different than the natural ratio such as deuterium 2 H (or D) in place of hydrogen 1 H (or H) or use of 13 C enriched material in place of 12 C and the like. Similar substitutions can be employed for N, O and S.
  • the use of isotopes may assist in analytical as well as therapeutic aspects of the invention. For example, use of deuterium may increase the in vivo half-life by altering the metabolism (rate) of the compounds of the invention.
  • These compounds can be prepared in accord with the preparations described by use of isotopically enriched reagents.
  • characterization of the compounds is performed according to the following methods.
  • Proton nuclear magnetic resonance ( 1 H NMR) and carbon nuclear magnetic resonance ( 13 C NMR) spectra were recorded on a Varian 300 or 600 MHz spectrometer in deuterated solvent.
  • Chemical shifts were reported as ⁇ (delta) values in parts per million (ppm) relative to tetramethylsilane (TMS) as an internal standard (0.00 ppm) and multiplicities were reported as s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad.
  • Data were reported in the following format: chemical shift (multiplicity, coupling constant(s) J in hertz (Hz), integrated intensity).
  • the mass spectrometry data were determined on a Shimadzu LCMS-IT-TOF instrument.
  • the formation of the hybrid compounds was checked by 1 H-NMR, comparing the chemical shifts of the protons from the CH 2 group identified in the schemes shown below, and identified as “CH 2 c ” for the starting material and as “CH 2 c* ” or “c*” for of the corresponding protons on the newly formed hybrid molecule wherein “*” indicates the hybrid compound.
  • Applicants have marked with arrows the location of these protons and the reaction site of the prodrug moiety, where available.
  • Each scheme shows the formation of the new hybrid drug.
  • Each table describes the results for the new hybrid drug and the linker number, where existing.
  • the linker moiety numbers are as described in Table 1.
  • Human recombinant carboxylesterases were purchased from a commercial vendor (BD GentestTM, Bedford, Mass.). All metabolic stability experiments were performed in triplicate in 96-well plate format.
  • the samples were analyzed by liquid chromatography with mass spectrometry (LC-MS/MS) detection to determine the metabolite concentrations resulting from the metabolism of the hybrid compounds.
  • Internal standards were used to compensate for variability from sample processing, chromatographic elution, mass spectrometer response and ion suppression by matrix components.
  • Table 9 lists the rate of metabolite formation in human recombinant carboxylesterases.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Botany (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
US14/199,514 2013-03-08 2014-03-06 Steroid conjugates Abandoned US20140256696A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/199,514 US20140256696A1 (en) 2013-03-08 2014-03-06 Steroid conjugates

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361775216P 2013-03-08 2013-03-08
US14/199,514 US20140256696A1 (en) 2013-03-08 2014-03-06 Steroid conjugates

Publications (1)

Publication Number Publication Date
US20140256696A1 true US20140256696A1 (en) 2014-09-11

Family

ID=50382692

Family Applications (4)

Application Number Title Priority Date Filing Date
US14/199,310 Abandoned US20140256658A1 (en) 2013-03-08 2014-03-06 Antibiotic Conjugates
US14/199,212 Abandoned US20140256694A1 (en) 2013-03-08 2014-03-06 Steroid antibiotic conjugates
US14/199,432 Active 2034-05-25 US9402913B2 (en) 2013-03-08 2014-03-06 Cyclosporine A steroid conjugates
US14/199,514 Abandoned US20140256696A1 (en) 2013-03-08 2014-03-06 Steroid conjugates

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US14/199,310 Abandoned US20140256658A1 (en) 2013-03-08 2014-03-06 Antibiotic Conjugates
US14/199,212 Abandoned US20140256694A1 (en) 2013-03-08 2014-03-06 Steroid antibiotic conjugates
US14/199,432 Active 2034-05-25 US9402913B2 (en) 2013-03-08 2014-03-06 Cyclosporine A steroid conjugates

Country Status (16)

Country Link
US (4) US20140256658A1 (fr)
EP (2) EP2964269A1 (fr)
JP (1) JP2016510754A (fr)
KR (1) KR20150125663A (fr)
CN (1) CN105025929A (fr)
AR (2) AR095072A1 (fr)
AU (1) AU2014225637A1 (fr)
BR (1) BR112015021388A2 (fr)
CA (1) CA2899500A1 (fr)
CL (1) CL2015002210A1 (fr)
IL (1) IL240920A0 (fr)
PH (1) PH12015501857A1 (fr)
RU (1) RU2015135145A (fr)
SG (1) SG11201507241UA (fr)
TW (2) TW201511768A (fr)
WO (4) WO2014138403A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9402913B2 (en) 2013-03-08 2016-08-02 Allergan, Inc. Cyclosporine A steroid conjugates
US9402912B2 (en) 2013-03-08 2016-08-02 Allergan, Inc. Antibiotic conjugates directly linked with steroid drugs
US10588862B2 (en) 2018-02-02 2020-03-17 Ripple Therapeutics Corporation Dexamethasone prodrug compositions and uses thereof
US11279729B2 (en) 2020-05-01 2022-03-22 Ripple Therapeutics Corporation Heterodimer compositions and methods for the treatment of ocular disorders
US12473326B2 (en) 2019-02-01 2025-11-18 Ripple Therapeutics Corporation Crystalline forms of dexamethasone dimers and uses thereof
US12509469B2 (en) 2020-08-06 2025-12-30 Ripple Therapeutics Corporation Compositions and methods for the treatment of pain and dependence disorders

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3048785A1 (fr) 2017-01-03 2018-07-12 The University Of North Carolina At Chapel Hill Alginates liberant de l'oxyde nitrique en tant qu'echafaudages antibacteriens biodegradables et procedes associes
CN110461338A (zh) 2017-03-28 2019-11-15 北卡罗来纳大学查佩尔希尔分校 作为可生物降解抗菌支架的释放一氧化氮的聚氨基糖苷类和其制备方法
CA3082130A1 (fr) 2017-11-15 2019-05-23 The University Of North Carolina At Chapel Hill Composes hyper-ramifies liberant de l'oxyde nitrique en tant qu'echafaudages antibacteriens et procedes associes
CA3091458A1 (fr) 2018-03-06 2019-09-12 The University Of North Carolina At Chapel Hill Cyclodextrines liberant de l'oxyde nitrique en tant qu'echafaudages antibacteriens biodegradables et procedes s'y rapportant
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
CA3110250A1 (fr) * 2018-08-22 2020-02-27 Bacainn Therapeutics, Ltd. Compositions de cyclosporine et methodes d'utilisation
MX2021002380A (es) 2018-08-31 2021-07-15 Aerie Pharmaceuticals Inc Conjugados de isoquinolina-esteroide y usos de los mismos.
EP3902841B1 (fr) 2018-12-28 2025-01-29 The University of North Carolina at Chapel Hill Polymères antibactériens libérant de l'oxyde nitrique et échafaudages fabriqués à partir de ceux-ci et procédés s'y rapportant
WO2023079362A1 (fr) * 2021-11-03 2023-05-11 Ripple Therapeutics Corporation Compositions aptes à être traitées et leur utilisation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2999102A (en) * 1959-10-14 1961-09-05 Thomae Gmbh Dr K Bis-(steroid-21)-dicarboxylic acid esters
US20030118528A1 (en) * 2001-11-19 2003-06-26 Walters Kenneth A. Topical delivery of codrugs

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3147183A (en) 1962-04-16 1964-09-01 Boehringer Sohn Ingelheim Bis-(steroid-21)-dicarboxylic acid esters
US3916002A (en) 1973-12-17 1975-10-28 Taubert Hans Dieter Oligomeric steroid esters, process for their production, and therapeutic compositions containing the same
EP0194972B1 (fr) 1985-03-11 1992-07-29 Sandoz Ag Cyclosporines
JPH089597B2 (ja) 1986-01-21 1996-01-31 杏林製薬株式会社 選択毒性に優れた８‐アルコキシキノロンカルボン酸およびその塩並びにその製造方法
US4839342A (en) 1987-09-03 1989-06-13 University Of Georgia Research Foundation, Inc. Method of increasing tear production by topical administration of cyclosporin
WO1994016330A1 (fr) 1993-01-06 1994-07-21 Beckman Instruments, Inc. Procede de preparation d'un preconjugue
US5688792A (en) 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
CA2136803A1 (fr) 1993-12-22 1995-06-23 Kazumi Ogata Derives de steroides
PT740650E (pt) 1994-01-28 2004-10-29 Univ Kentucky Res Found Co-farmacos como um metodo de administracao controlada de farmacos
US6051576A (en) 1994-01-28 2000-04-18 University Of Kentucky Research Foundation Means to achieve sustained release of synergistic drugs by conjugation
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
US5565568A (en) 1995-04-06 1996-10-15 Eli Lilly And Company 2-acylaminopropanamides as tachykinin receptor antagonists
US6350422B1 (en) 1998-09-21 2002-02-26 Phillips Petroleum Company Sorbent compositions
US6254860B1 (en) 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
AU4934299A (en) 1999-07-15 2001-02-05 Kuhnil Pharm. Co., Ltd. Novel water soluble-cyclosporine conjugated compounds
US20010049366A1 (en) * 2000-02-09 2001-12-06 Alcon Universal Ltd. Topical solution formulations containing an antibiotic and a corticosteroid
US6306842B1 (en) 2000-06-02 2001-10-23 Medinox, Inc. Protected forms of a combination of pharmacologically active agents and uses therefor
BR0209198A (pt) 2001-04-26 2004-06-08 Control Delivery Sys Inc Métodos de sìntese de compostos contendo fenol
WO2003031443A1 (fr) 2001-10-04 2003-04-17 Morphochem Aktiengesellschaft für kombinatorische Chemie Antibiotiques a action duale renfermant une oxazolidinone et une quinolone ou une fraction de naphthyridinone
WO2003031441A1 (fr) 2001-10-04 2003-04-17 Morphochen Aktiengesellschaft Für Kombinatorische Chemie Composes a actions multiples
AUPR879601A0 (en) * 2001-11-09 2001-12-06 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
EP1603512A2 (fr) 2003-03-17 2005-12-14 Albany Molecular Research, Inc. Nouvelles cyclosporines
HRP20030324A2 (en) 2003-04-24 2005-02-28 Pliva-Istra�iva�ki institut d.o.o. Compounds of antiinflammatory effect
US20070155714A1 (en) 2003-04-30 2007-07-05 Morphochem Aktiengesellschaft Fur Kombinatorische Chemie Use of oxazolidinone-quinoline hybrid antibiotics for the treatment of anthrax and other infections
EP1633403A2 (fr) 2003-05-21 2006-03-15 Control Delivery Systems, Inc. Medicaments combines contenant du diclofenac
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US20060105941A1 (en) * 2004-11-12 2006-05-18 Allergan, Inc. Mixed antibiotic codrugs
US7288520B2 (en) 2005-07-13 2007-10-30 Allergan, Inc. Cyclosporin compositions
JP2009528292A (ja) 2006-02-27 2009-08-06 ザ ボード オブ トラスティーズ オブ レランド スタンフォード ジュニア ユニバーシティ 生物学的障壁を越える増強された放出特性を有する分子の輸送のための組成物および方法
WO2008094507A2 (fr) 2007-01-26 2008-08-07 Cellicon Biotechnologies, Inc. Nouveaux composés de fusion
ITMI20080382A1 (it) 2008-03-07 2009-09-08 Ctg Pharma S R L Composizioni farmaceutiche oculari
BRPI0915552A2 (pt) 2008-07-10 2017-06-20 Allergan Inc derivados de ciclosporina, seu uso e sua composição farmacêutica
MX2008014515A (es) * 2008-09-09 2010-04-29 Allergan Inc Suspension oftalmica para uso ocular.
WO2010113151A1 (fr) * 2009-03-31 2010-10-07 Technion Research & Development Foundation Ltd. Agents antimicrobiens conjugués
JP2012528163A (ja) 2009-05-27 2012-11-12 アラーガン、インコーポレイテッド 炎症性疾患および状態を処置するためのシクロスポリン誘導体
RU2013120927A (ru) 2010-10-12 2014-11-20 Аллерган, Инк. Аналоги циклоспорина
BR112013008864A2 (pt) 2010-10-12 2016-06-28 Allergan Inc análogos d ciclosporina
PH12014500596A1 (en) 2011-09-16 2014-04-21 Davidson Lopez Llc Plant steroids and uses thereof
AU2013267435B2 (en) 2012-06-01 2017-11-09 Allergan, Inc. Cyclosporin A analogs
KR20150126032A (ko) 2013-03-08 2015-11-10 알러간, 인코포레이티드 스테로이드 약물과 직접 결합된 항생제 컨쥬게이트
WO2014138343A1 (fr) 2013-03-08 2014-09-12 Allergan, Inc. Conjugués d'antibiotiques avec des médicaments anti-inflammatoires non stéroïdiens
JP2016510753A (ja) 2013-03-08 2016-04-11 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ ステロイド薬と結合した抗生物質共役体
EP2964269A1 (fr) 2013-03-08 2016-01-13 Allergan, Inc. Conjugués stéroïde/cyclosporine a

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2999102A (en) * 1959-10-14 1961-09-05 Thomae Gmbh Dr K Bis-(steroid-21)-dicarboxylic acid esters
US20030118528A1 (en) * 2001-11-19 2003-06-26 Walters Kenneth A. Topical delivery of codrugs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Avunduk et al., The Comparison of Efficacies of Topical Corticosteroids and Nonsteroidal Anti-inflammatory Drops on Dry Eye Patients: A Clinical and Immunocytochemical Study, October 2003, American Journal of Ophthalmology, Vol. 136, No. 4, pp. 593-602 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9402913B2 (en) 2013-03-08 2016-08-02 Allergan, Inc. Cyclosporine A steroid conjugates
US9402912B2 (en) 2013-03-08 2016-08-02 Allergan, Inc. Antibiotic conjugates directly linked with steroid drugs
US10588862B2 (en) 2018-02-02 2020-03-17 Ripple Therapeutics Corporation Dexamethasone prodrug compositions and uses thereof
US10632075B2 (en) 2018-02-02 2020-04-28 Ripple Therapeutics Corporation Glass formulations and uses thereof
US10945958B2 (en) 2018-02-02 2021-03-16 Ripple Therapeutics Corporation Dexamethasone prodrug compositions and uses thereof
US10959954B2 (en) 2018-02-02 2021-03-30 Ripple Therapeutics Corporation Dexamethasone prodrug compositions and uses thereof
US11612567B2 (en) 2018-02-02 2023-03-28 Ripple Therapeutics Corporation Ocular inserts comprising a covalently linked steroid dimer
US12473326B2 (en) 2019-02-01 2025-11-18 Ripple Therapeutics Corporation Crystalline forms of dexamethasone dimers and uses thereof
US11279729B2 (en) 2020-05-01 2022-03-22 Ripple Therapeutics Corporation Heterodimer compositions and methods for the treatment of ocular disorders
US12509469B2 (en) 2020-08-06 2025-12-30 Ripple Therapeutics Corporation Compositions and methods for the treatment of pain and dependence disorders

Also Published As

Publication number Publication date
CA2899500A1 (fr) 2014-09-12
EP2964268A1 (fr) 2016-01-13
CN105025929A (zh) 2015-11-04
WO2014138403A1 (fr) 2014-09-12
WO2014138359A1 (fr) 2014-09-12
AU2014225637A1 (en) 2015-09-03
US9402913B2 (en) 2016-08-02
US20140256694A1 (en) 2014-09-11
WO2014138425A1 (fr) 2014-09-12
SG11201507241UA (en) 2015-10-29
US20140256658A1 (en) 2014-09-11
AR095073A1 (es) 2015-09-16
CL2015002210A1 (es) 2016-01-22
WO2014138437A1 (fr) 2014-09-12
EP2964269A1 (fr) 2016-01-13
US20140256651A1 (en) 2014-09-11
TW201511758A (zh) 2015-04-01
AR095072A1 (es) 2015-09-16
TW201511768A (zh) 2015-04-01
JP2016510754A (ja) 2016-04-11
RU2015135145A (ru) 2017-04-13
PH12015501857A1 (en) 2015-12-07
KR20150125663A (ko) 2015-11-09
IL240920A0 (en) 2015-10-29
BR112015021388A2 (pt) 2017-07-18

Similar Documents

Publication Publication Date Title
US9402913B2 (en) Cyclosporine A steroid conjugates
US20250122153A1 (en) Protease Inhibitors as Antivirals
AU2022271435A1 (en) Ophthalmic compositions
US20140256660A1 (en) Antibiotic conjugates linked with steroid drugs
US20160318844A1 (en) Prostacyclin compounds, compositions and methods of use thereof
WO2015117136A1 (fr) Esters d'acide boronique et leurs formulations pharmaceutiques
US20200354395A1 (en) Antimicrobial compounds, compositions, and uses thereof
JP2024038482A (ja) 標識オキシトシンならびに製造および使用の方法
US20140256666A1 (en) Antibiotic conjugates with nonsteroidal anti-inflammatory drugs
US9402912B2 (en) Antibiotic conjugates directly linked with steroid drugs
US9938316B2 (en) Selective inhibitors of α2 isoform of Na,K-ATPase and use thereof for reduction of intra-ocular pressure and as cardiotonic agents
JP2018502851A (ja) アムホテリシンｂの尿素誘導体の簡便な合成法
US10711040B2 (en) Low substituted polymyxins and compositions thereof
CN118829423A (zh) 用于将有效载荷分子递送至气道上皮的组合物
US10010616B2 (en) Immunogenic compositions and reagents for preparing
US20250109171A1 (en) Compounds and compositions for targeted therapy of renal diseases
US20250281419A1 (en) Lipid amines
NZ719297A (en) Prostacyclin compounds, compositions and methods of use thereof

Legal Events

Date Code Title Description
AS Assignment

Owner name: ALLERGAN, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SINHA, SANTOSH C.;CHOW, KEN;WANG, LIMING;AND OTHERS;SIGNING DATES FROM 20140226 TO 20140228;REEL/FRAME:032369/0697

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION